Equities analysts expect that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report earnings per share of ($0.30) for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Collegium Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.12). Collegium Pharmaceutical posted earnings of ($0.45) per share during the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The business is expected to announce its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($1.41) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.19). For the next year, analysts forecast that the business will post earnings of $0.18 per share, with EPS estimates ranging from ($0.45) to $1.09. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. The business had revenue of $73.10 million for the quarter, compared to analysts’ expectations of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The firm’s quarterly revenue was up 1930.6% on a year-over-year basis.
In other news, COO Joseph Ciaffoni sold 79,683 shares of Collegium Pharmaceutical stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $22.59, for a total value of $1,800,038.97. Following the sale, the chief operating officer now directly owns 174,089 shares of the company’s stock, valued at $3,932,670.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alison B. Fleming sold 4,096 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $27.00, for a total value of $110,592.00. Following the completion of the sale, the insider now directly owns 53,362 shares in the company, valued at $1,440,774. The disclosure for this sale can be found here. Insiders sold 243,779 shares of company stock worth $5,980,331 over the last ninety days. Insiders own 25.76% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Wellington Shields Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $204,000. Atria Investments LLC bought a new stake in shares of Collegium Pharmaceutical in the second quarter worth about $201,000. EagleClaw Capital Managment LLC bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $220,000. Stifel Financial Corp bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $224,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $260,000. 92.35% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:COLL traded up $0.35 on Thursday, reaching $18.03. 970,816 shares of the company’s stock traded hands, compared to its average volume of 500,254. The company has a quick ratio of 0.80, a current ratio of 0.82 and a debt-to-equity ratio of 3.94. The stock has a market cap of $587.36 million, a PE ratio of -7.30 and a beta of 0.51. Collegium Pharmaceutical has a 12 month low of $9.01 and a 12 month high of $29.90.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Recommended Story: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.